Key facts
as of Sep 2026- It has raised $13.7M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Hana Ventures, Schmidt (South Korea), T.S. Investment, Bluepoint Partners, LogInvestment — 18 tracked in total.
- 1 institutional filer reports fund marks on NeogenTC across 7 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for NeogenTC
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in NeogenTC shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
1 filers · latest Oct 20251 SEC-registered fund reported 7 fair-value marks on NeogenTC between Apr 2025 and Oct 2025. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for NeogenTC are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeogenTC
Developer of cancer therapies designed to provide personalized anticancer treatment. The company offers engineered tumor-infiltrating lymphocyte therapies, T cell receptor-modified T cell development, and scientific research capabilities to administer cell therapy that can target solid cancers that are difficult to treat, enabling patients with cancer and the medical research community to access personalized immunotherapy that harnesses the body's immune system to target cancer cells and advance treatment options.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2020
- Employees
- 9
- Website
- neogentc.com/
- Ownership
- Privately Held (backing)